PHV02 for Nipah Virus

Phase-Based Progress Estimates
1
Effectiveness
1
Safety
Nipah VirusPHV02 - Biological
Eligibility
18 - 60
All Sexes
What conditions do you have?
Select

Study Summary

This trial is testing a new vaccine for the Nipah virus, to see if it is safe and effective in healthy adults.

Eligible Conditions
  • Nipah Virus

Treatment Effectiveness

Study Objectives

1 Primary · 0 Secondary · Reporting Duration: 42 days after vaccination

42 days after vaccination
Number of participants with treatment-related adverse events as assessed by the Toxicity Grading Scale

Trial Safety

Trial Design

4 Treatment Groups

PHV02 2x10^7 pfu
1 of 4
PHV02 2x10^6 pfu
1 of 4
PHV02 2x10^5 pfu
1 of 4
Placebo
1 of 4

Experimental Treatment

Non-Treatment Group

60 Total Participants · 4 Treatment Groups

Primary Treatment: PHV02 · Has Placebo Group · Phase 1

PHV02 2x10^7 pfu
Biological
Experimental Group · 1 Intervention: PHV02 · Intervention Types: Biological
PHV02 2x10^6 pfu
Biological
Experimental Group · 1 Intervention: PHV02 · Intervention Types: Biological
PHV02 2x10^5 pfu
Biological
Experimental Group · 1 Intervention: PHV02 · Intervention Types: Biological
Placebo
Other
PlaceboComparator Group · 1 Intervention: Placebo · Intervention Types: Other

Trial Logistics

Logistics

Participation is compensated

You will be compensated for participating in this trial.

Trial Timeline

Screening: ~3 weeks
Treatment: Varies
Reporting: 42 days after vaccination

Who is running the clinical trial?

Coalition for Epidemic Preparedness InnovationsOTHER
31 Previous Clinical Trials
75,004 Total Patients Enrolled
Public Health Vaccines LLCLead Sponsor
Carlos Fierro, MDPrincipal InvestigatorJohnson County Clinical Trials
6 Previous Clinical Trials
1,018 Total Patients Enrolled
Thomas Monath, MD, FASTMHStudy DirectorCrozet BioPharma

Eligibility Criteria

Age 18 - 60 · All Participants · 7 Total Inclusion Criteria

Mark “Yes” if the following statements are true for you:
You are healthy, adult, male or non-pregnant, non-lactating females.
You agree to avoid conception through Day 29.
You agree to avoid employment in industry involved with livestock after vaccination through Day 29.